Gut Microbiome Analysis for Early Parkinson's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases like Parkinson's Disease are ineffective for early detection, as they rely on symptom emergence, and there is a need for new approaches to facilitate early intervention.
Innovation Solution
Identification of specific gut microbial species, such as Roseburia faecis, Faecalibacterium prausnitzii, Clostridium_fessum, Dysosmobacter_welbionis, Lachnospira_pectinoschiza, Clostridium_sp_AM22_11AC, Anaerotruncus_colihominis, and Clostridiales_Family_XIII_bacterium_BX16, through fecal sample analysis using metagenomic sequencing to calculate a probability score for early detection of prodromal Parkinson's Disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods relying on symptom emergence are used, then diagnosis can be made with existing clinical criteria, but early detection before symptom emergence is not achieved
Solution Approach 1:
The patent applies preliminary action by detecting gut microbial species composition changes that occur before classical Parkinson's disease symptoms emerge. The method identifies prodromal stage pathogens through fecal sample analysis, enabling diagnosis and intervention prior to symptom manifestation, thus achieving early detection without requiring complex neurological examination equipment
Solution Approach 2:
The patent uses gut microbial species composition as an intermediary biomarker to detect prodromal Parkinson's disease. Instead of directly measuring neurological changes, the method analyzes microbial pathogens in fecal samples as a surrogate indicator, simplifying the diagnostic approach while achieving early detection capability
2Measurement precision
If invasive neurological examinations are performed for early detection, then diagnostic accuracy may improve, but patient comfort and accessibility deteriorate
Solution Approach 1:
The patent enables self-service diagnostic sampling by using fecal samples that patients can easily collect at home without requiring medical professional intervention. This non-invasive approach maintains high diagnostic accuracy for prodromal Parkinson's detection while dramatically improving patient accessibility and comfort compared to invasive neurological examinations
Solution Approach 2:
The patent extracts the diagnostic function from complex neurological examinations and relocates it to simple fecal sample analysis. By taking out the pathogen detection function and applying it to gut microbial analysis, the method achieves accurate early detection while eliminating the need for sophisticated neurological testing equipment and specialist involvement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive, early detection of prodromal Parkinson's Disease and elevated risk assessment, allowing for timely therapeutic interventions.
Implementation Method 1
The method include these steps: first, determining in a fecal sample taken from the subject the amount of each of the bacterial species according to the following designations
Implementation Method 2
In some embodiments, the first step comprises DNA extraction and metagenomic sequencing
Data Source
AI summary
The present invention provides for compositions and methods for the early detection of prodromal Parkinson's Disease as well as for early medical intervention, especially among individual who may not have been diagnosed but are at an elevated risk of later developing Parkinson's Disease and related conditions.